Showing 1531-1540 of 1603 results for "".
- ADCS Acquires More Clinicshttps://practicaldermatology.com/news/20121106-adcs_acquires_more_clinics/2459683/After announcing a major acquisition of multiple clinics on Florida's West Coast, Advanced Dermatology & Cosmetic Surgery (ADCS) has acquired two clinics in the Florida Keys from the practice of Dr. Karen Weismantle. The clinics are
- Provectus Presents Data on PV-10 in Combination with Systemic Chemotherapyhttps://practicaldermatology.com/news/20121029-provectus_presents_data_on_pv-10_in_combination_with_systemic_chemotherapy/2459688/Provectus Pharmaceuticals, Inc. presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD. PV-10 is Provectus Pharmaceuticals' novel oncology drug design
- LEO Pharma's Taclonex Topical Suspension Approved for Body Plaqueshttps://practicaldermatology.com/news/20121029-leo_pharma_receives_fda_approval_for_taclonex_topical_suspension/2459689/LEO Pharma Inc. announced the US Food and Drug Administration (FDA) approval of Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of body plaque psoriasis. Taclonex® Topical Suspension is
- ADCS Clinics Adds New Providers in Floridahttps://practicaldermatology.com/news/20121024-adcs_clinics_adds_new_providers_in_florida/2459694/After announcing a major acquisition of multiple clinics on Florida's West Coast, Advanced Dermatology & Cosmetic Surgery (ADCS) has acquired multiple practices throughout Florida. ADCS has added six new dermatologists to the practi
- Suneva Medical Completes Initial Treatment in Phase 3 Acne Scar Studyhttps://practicaldermatology.com/news/20121024-suneva_medical_completes_initial_treatment_in_phase_3_acne_scar_study/2459695/Suneva Medical, Inc. announced that it has completed the enrollment and initial treatment of patients in its Phase 3 acne scar study. This multi-center, prospective study is investigating the efficacy of Artefill for the treatment of moderate to
- STELARA Wins 2012 International Prix Galien Awardhttps://practicaldermatology.com/news/20121022-stelara_wins_2012_international_prix_galien_award/2459698/Janssen Biotech, Inc. announced that STELARA was named the 2012 International Prix Galien award winner in Lyon, France. The honor is acknowledgment of the technical, scientific, and clinical research skills necessary to develop innovative medicines and devices. The international Prix Galien Award is
- Nuvo and Galderma Win FDA Approval for Topical Peelhttps://practicaldermatology.com/news/20121022-nuvo_and_galderma_win_fda_approval_for_topical_peel/2459699/Nuvo Research announced that the FDA has approved its Pliaglis product, a topical anesthetic cream designed to minimize pain during aesthetic dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. The approval
- ASDS: Study Shows that PCPs Favor Dermatologists for Cosmetic Procedureshttps://practicaldermatology.com/news/20121016-new_study_from_asds_shows_that_pcps_favor_dermatologists_for_cosmetic_procedures/2459705/Recent survey data presented at the recent ASDS Meeting in Atlanta and published in the October edition of Dermatologic Surgery finds that almost two-thirds of physicians chose dermatologists as the most qualified to perform cosmetic procedures for wrinkles and skin rejuvenation. Additionally, resul
- ADCS Clinics Acquires Additional Practicehttps://practicaldermatology.com/news/20121010-adcs_clinics_acquires_additional_practice/2459710/Less than a week after announcing a major acquisition of multiple clinics on Florida's West Coast, Advanced Dermatology & Cosmetic Surgery (ADCS) announced the acquisition of Winter Park Dermatology. The practice is located in Wint
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.